Merck Serono

Merck Serono is a division of the global pharmaceutical and chemical group Merck KGaA, based in Darmstadt, Germany. It specializes in innovative prescription drugs, used to treat cancer, multiple sclerosis, infertility, endocrine and metabolic disorders, as well as cardiovascular diseases.

History[edit | edit source]

Merck Serono was established in 2007 following the acquisition of Swiss biotechnology company Serono by Merck KGaA. The merger combined Merck's strong capabilities in chemicals and pharmaceuticals with Serono's expertise in biotechnology.

Products[edit | edit source]

Merck Serono's product portfolio includes drugs for the treatment of cancer, multiple sclerosis, infertility, endocrine disorders, and metabolic disorders. Some of its well-known products include Rebif, a drug for the treatment of multiple sclerosis, and Erbitux, a monoclonal antibody used in cancer therapy.

Research and Development[edit | edit source]

Merck Serono is committed to discovering and developing innovative therapies that can improve patient health and quality of life. The company's research and development activities focus on a wide range of therapeutic areas, including oncology, neurology, immunology, and endocrinology.

Global Presence[edit | edit source]

Merck Serono operates in more than 150 countries around the world. Its global headquarters are located in Darmstadt, Germany, with major research and development centers in Switzerland, the United States, and Germany.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.